Financial Data and Key Metrics Changes - Adjusted diluted earnings per share increased by 3.6% in Q3 and by 5.9% for the first nine months [18] - Adjusted operating companies income (OCI) for smokeable products grew by 0.7% to nearly $3 billion in Q3 and by 2.5% to $8.4 billion for the first nine months [18] - Adjusted OCI margins expanded to 64.4% for both Q3 and the first nine months, representing margin growth of 1.3 percentage points and 2.7 percentage points respectively [18] Business Line Data and Key Metrics Changes - Domestic cigarette volumes declined by 8.2% in Q3 and 10.6% for the first nine months when adjusted for trade inventory movements [18] - Marlboro expanded its share of the premium segment by 0.3 to 59.6% in Q3 [19] - The oral tobacco products segment saw adjusted OCI decline by less than 1% in Q3, but adjusted OCI margin expanded by 2.4 percentage points to 69.2% for the first nine months [22] Market Data and Key Metrics Changes - The nicotine pouch category grew to 55.7 share points, an increase of 11.1 share points year over year [5] - The e-vapor category included approximately 21 million vapers, up nearly 2 million versus a year ago [11] - Retail share for oral tobacco products was 31.1% for Q3 and 32.9% for the first nine months [23] Company Strategy and Development Direction - The company is focusing on expanding its smoke-free portfolio and exploring international opportunities in innovative smoke-free products [4][15] - A collaboration with KT&G was announced to explore opportunities in international innovative smoke-free products and non-nicotine products [4][16] - The company aims to maintain profitability in the premium segment while also investing in the discount segment to capture price-sensitive consumers [20][21] Management's Comments on Operating Environment and Future Outlook - Management noted that consumer spending remains under pressure due to macroeconomic factors, but they are optimistic about maintaining profitability [30] - The company raised the lower end of its 2025 guidance range, expecting adjusted diluted EPS in the range of $5.37 to $5.45 [24] - Management emphasized the importance of a functioning regulatory system and the need for accelerated product authorizations from the FDA [14][54] Other Important Information - The company returned nearly $6 billion to shareholders, including $5.2 billion in dividends and $712 million in share repurchases [25] - The board authorized the expansion of the share repurchase program from $1 billion to $2 billion, which now expires on December 31, 2026 [25] Q&A Session Summary Question: Insights on fourth quarter earnings growth deceleration - Management acknowledged the impact of share repurchase and MSA legal fund expiration on earnings growth, while monitoring consumer spending [29][30] Question: Drivers behind the moderation in cigarette industry decline - Management indicated that consistency in gas prices and inflation may have contributed to the moderation in decline [31][32] Question: Performance and positioning of ON in the nicotine pouch category - Management expressed satisfaction with ON's performance despite competitive pressures and highlighted the importance of retail takeaway volume [33][34] Question: Opportunities from the KT&G partnership - Management discussed three pronged opportunities: expanding ON internationally, exploring non-nicotine products, and improving operational efficiencies [36][39] Question: Clarification on duty drawbacks and EPS growth - Management stated that duty drawbacks are an additional benefit but emphasized the need for a functioning regulatory system for long-term decisions [52][54] Question: Impact of FDA pilot program on ON+ launch - Management clarified that decisions will be based on long-term interests and the functioning of the regulatory system [53][54]

Core Viewpoint - Altria Group, known for its Marlboro brand, faces an uncertain future despite its history of consistent dividend increases and dominance in the tobacco market [1][2]. Industry Transition - The tobacco industry is shifting from combustible cigarettes to smoke-free products, with Altria's ability to adapt to these trends being crucial for its long-term viability [2][5]. - The U.S. tobacco market remains lucrative, with Altria holding a 41% share of the retail cigarette market and 59.5% of the premium segment [4]. Product Development Challenges - Altria has struggled to establish itself in the next-generation product categories, including electronic vapes and heated tobacco devices, following a failed investment in Juul and a recent patent loss [5][6][7]. - Oral nicotine salt pouches have been Altria's most successful smoke-free product, but it still lags behind competitors like Philip Morris International's Zyn [8]. Financial Performance - In Q2 2025, approximately 83% of Altria's operating income came from smokeable products, indicating that smoke-free products are not yet a significant revenue source [9]. - The legacy smokeable segment remains profitable, allowing Altria to slowly increase free cash flow per share through price hikes and stock repurchases [10]. Dividend and Growth Outlook - Altria recently raised its dividend by 3.9%, offering a starting yield of 6.5%, with analysts projecting an average earnings growth of 3.4% annually over the next three to five years [11][12]. - The company is expected to maintain steady dividend growth for at least another five years, provided it can improve its performance in next-generation products [12]. Distribution Network Advantage - Altria's extensive distribution network, built through its Marlboro brand, positions it to potentially regain market share in new product categories if it executes effectively [13]. Investment Considerations - Altria is considered a strong high-yield dividend stock, appealing to investors seeking steady income, though it may not be suitable for those looking for high growth and capital gains [14][15]. - The company must enhance its product rollout and market presence in the transitioning nicotine industry to secure its long-term position [16].